Sun Pharmaceutical said on Saturday it proposed to fully acquire Israel-based Taro Pharmaceutical Industries through a reverse triangular merger. In the all-cash deal, Sun Pharma will acquire the shares at a price of $38 per ordinary share which will be payable in full at the closing of the
proposed transaction. Sun Pharma currently owns a 78.48% stake in Taro.